Articles related to Oncology, Radiation

To define the spectrum of alterations common at relapse, the researchers in this study performed integrated profiling of 136 relapsed pediatric AML cases with RNA sequencing (RNA-seq), whole-genome sequencing, and target-capture sequencing. In addition, well-characterized fusion oncoproteins were identified, as were somatic mutations in UBTF (upstream binding transcription factor). See the results from the late-breaking abstract being presented at the ASH Annual Meeting & Exhibition.

In this late-breaking abstract from the ASH Annual Meeting & Exhibition, the researches wanted to address the limited understanding of how and when CH develops, what factors govern its behavior, how it interacts with aging, and how these variables relate to malignant progression. Here are the results from analyzing 1,593 blood DNA samples from 385 elderly individuals, each sampled up to 5 times over approximately 13 years.

A late-breaking abstract from the ASH Annual Meeting & Exhibition. In this double-blind, placebo-controlled, international study of 879 patients (median age: 65 (range 19–80) years; IPI 3–5 (62%)), the pola-R-CHP combination demonstrated a 27% reduction in the relative risk of disease progression, relapse, or death compared with R-CHOP, with a similar safety profile in the first-line treatment of patients with DLBCL.

Let’s be honest, some medical specialties are easier than others, offering better hours at higher rates of pay and with less stress. However, for every doctor whose specialty affords them time on the golf course, there are other specialties that leave physicians trapped in a spiraling cycle of unpredictable hours, bad pay, and terrible work-life balance. How does your specialty measure up?

Only about half of doctors in America identify themselves as “millionaires.” Like the rest of us, many physicians need to invest their money to grow it and build a retirement fund. And, increasingly, doctors are following the lead of the super-rich and investing in art. One-percenters are increasingly putting their money into art, which offers superior returns to the stock market averages with less risk and stress. Over time, the price of art tends to move in one direction — upwards — whereas stock prices can gyrate wildly and are prone to extreme volatility.

A randomized phase II trial has found that consolidation therapy with nivolumab (Opdivo) plus ipilimumab (Yervoy) after chemoradiotherapy did not lead to better survival outcomes for patients with small cell lung cancer (SCLC). The study enrolled 222 patients with stage I-IIIB histologically or cytologically confirmed limited-disease SCLC, and adequate hematologic, renal, lung, and pulmonary function. The combination regimen yielded no improvement in overall survival, and grade 3 adverse events were approximately 2.5 times more common in the dual therapy group.